The FDA has been mulling over several issues on social media since the Section 15 Hearings in 2009. It has, at long last, issued Draft Guidance on Off-label Inquiries conveyed through social media. Significantly, a company’s response that follows the Draft Guidance, if the Guidance is finalized as is, will not be considered proof of [...]